Active substanceCholine alfoscerateCholine alfoscerate
Similar drugsTo uncover
  • Alphofolin-Lekpharm
    solution w / m in / in 
    LEKFARM, SOOO     Republic of Belarus
  • Glacer
    solution w / m in / in 
    EKOFARMPLUS, CJSC     Russia
  • Gliatilin
    solution w / m d / infusion 
    Italfarmaco SpA     Italy
  • Gliatilin
    capsulessolution inwards w / m in / in 
    Italfarmaco SpA     Italy
  • Gliatilin
    capsulessolution inwards w / m in / in 
    Italfarmaco SpA     Italy
  • Gliatilin
    solution inwards 
    Italfarmaco SpA     Italy
  • Delecite
    solution w / m d / infusion 
    ITF, LLC     Russia
  • Delecite
    capsules inwards 
    ITF, LLC     Russia
  • Noochlin Rompharm
    solution w / m in / in 
  • Choline alfoscerate
    solution w / m in / in 
    Company DEKO, LLC     Russia
  • Choline alfoscerate
    solution w / m in / in 
    PharmIntelekt, OOO     Russia
  • Choline alfoscerate
    solution w / m in / in 
  • Choline alfoscerate
    solution w / m in / in 
    ATOLL, LLC     Russia
  • Choline alfoscerate
    solution w / m d / infusion 
    BIOSINTEZ, PAO     Russia
  • Choline alfoscerate
    solution inwards 
  • Holilitil
    solution w / m in / in 
    Company DEKO, LLC     Russia
  • Holilitil
    capsules inwards 
    ARTLIFE, LLC     Russia
  • Cerepro®
    solution w / m in / in 
    VEROPHARM SA     Russia
  • Cerepro
    capsulessolution inwards w / m in / in 
    VEROPHARM SA     Russia
  • Cereton®
    solution w / m in / in 
  • Cereton
    capsules inwards 
  • Cereton®
    solution inwards 
  • Dosage form: & nbsp
    Solution for intravenous and intramuscular injection, capsules.

    Composition:
    Solution for intramuscular and intravenous administration: 1 ml of the solution contains 250mg glycerylphosphorylcholine hydrate (choline alfoscerate) as an active ingredient; ancillary is water for injection.
    Capsules: one capsule contains 400 mg glycerylphosphorylcholine hydrate (choline alfoscerate) as an active ingredient; auxiliary substances: glycerol (glycyrin), purified water. Capsule Shell: Gelatin medical, glycerol (glycerine), methyl parahydroxybenzoate (methyl paraben), propyl parahydroxybenzoate (propylparaben), a coloring agent red iron oxide, titanium dioxide, purified water, sorbitol (sorbitol).
    Description:Solution for intramuscular and intravenous administration: clear, colorless liquid.
    Capsules: capsules are soft gelatinous, oblong in shape, from red to brown. The contents of capsules are oily, clear, colorless or slightly colored liquid
    Pharmacotherapeutic group:Nootropic agent.
    ATX: & nbsp

    N.07.A.X.02   Choline alfoscerate

    Pharmacodynamics:
    Central cholinostimulator, which contains 40.5% of metabolically protected choline (metabolic protection contributes to the release of choline in the brain). Upon ingestion, it is cleaved under the action of enzymes on choline and glycerophosphate: choline participates in the biosynthesis of acetylcholine, one of the main neurotransmitter mediators; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) neuronal membrane. Provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation. Increases the linear velocity of blood flow on the side of traumatic brain injury, contributes to the normalization of spatiotemporal characteristics of spontaneous bioelectrical activity of the brain; has a positive effect on the cognitive and behavioral responses of patients with cerebral vascular diseases.
    It improves brain functions, affecting the pathogenetic factors of the involutionary psychoorganic syndrome, changes the phospholipid composition of neuronal membranes and reduces cholinergic activity. Dose-dependent stimulation of acetylcholine release; participating in the synthesis of phosphatidylcholine (membrane phospholipid), improves synaptic transmission, plasticity of neuronal membranes, receptor function. Does not affect the reproductive cycle and does not have a teratogenic and mutagenic effect.
    Pharmacokinetics:Absorption - 88%, easily penetrates the blood-brain barrier (with oral intake, the concentration in the brain is 45% of that in the plasma). It is mainly excreted in the lungs, in the form of carbon dioxide (85%), as well as by the kidneys and through the intestine (15%).
    Indications:
    - acute and recovery periods of severe craniocerebral trauma and ischemic stroke, the recovery period of hemorrhagic stroke, with focal hemispheric symptoms or symptoms of brain stem damage;
    - chronic cerebral circulatory failure;
    - Cognitive disorders (impaired mental function, memory, confusion, disorientation, decreased motivation,initiative and ability to concentrate attention) including in dementia and encephalopathy.
    - senile pseudo-melancholy.
    - psychoorganic syndrome in the background of degenerative and involuntary changes in the brain;
    Contraindications:Hypersensitivity, pregnancy, breastfeeding.
    Dosing and Administration:
    In acute conditions: intramuscularly or intravenously (slowly) 1.0 g (1 ampoule) per day for 10-15 days, then switch to capsule intake by 0.8 g (2 capsules) in the morning and 0.4 g (1 capsule) in the afternoon within 6 months.
    For chronic conditions: inside by 0.4 g (1 capsule) 3 times a day, preferably before meals. Duration of treatment is 3-6 months.
    Side effects:Allergic reactions, nausea (due to dopaminergic activation).
    Overdose:Symptoms: dyspeptic disorders. Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.
    Interaction:not found.
    Special instructions:If there is nausea after taking the drug should reduce the dose. Cerepro does not affect the speed of psychomotor reactions.
    Form release / dosage:Solution for intravenous and intramuscular injection 250 mg / ml.
    Capsules 400 mg.
    Packaging:
    A solution for intravenous and intramuscular injection of 250 mg / ml in ampoules of 4 ml. For 3, 5 or 10 ampoules, together with instructions for use in a box of cardboard or 3 or 5 ampoules in a contour cell package. For 1 or 2 contour squares together with instructions for use in a pack of cardboard.
    Capsules 400 mg: 10 or 14 capsules per cell container. For 10 or 14 capsules in a jar of lightproof glass. Each jar or 1 or 2 contourcell packs of 14 capsules, or 1 or 3 contour packs of 10 capsules, together with instructions for use in a pack of cardboard.
    Storage conditions:
    In a dry, protected from light place at a temperature of no higher than 25 ° C.
    Keep out of the reach of children.
    Shelf life:
    The solution for intramuscular and intravenous administration is 2 years.
    Capsules - 2 years.
    Do not use after the time specified on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:LS-000475
    Date of registration:31.05.2010
    The owner of the registration certificate:VEROPHARM SA VEROPHARM SA Russia
    Manufacturer: & nbsp
    Information update date: & nbsp26.09.2015
    Illustrated instructions
      Instructions
      Up